Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial.

Autor: Lingas, Guillaume, Néant, Nadège, Gaymard, Alexandre, Belhadi, Drifa, Peytavin, Gilles, Hites, Maya, Staub, Thérèse, Greil, Richard, Paiva, Jose-Artur, Poissy, Julien, Peiffer-Smadja, Nathan, Costagliola, Dominique, Yazdanpanah, Yazdan, Wallet, Florent, Gagneux-Brunon, Amandine, Mentré, France, Ader, Florence, Burdet, Charles, Guedj, Jérémie, Bouscambert-Duchamp, Maude
Předmět:
Zdroj: Journal of Antimicrobial Chemotherapy (JAC); May2022, Vol. 77 Issue 5, p1404-1412, 9p
Abstrakt: Background: The antiviral efficacy of remdesivir in COVID-19 hospitalized patients remains controversial.Objectives: To estimate the effect of remdesivir in blocking viral replication.Methods: We analysed nasopharyngeal normalized viral loads from 665 hospitalized patients included in the DisCoVeRy trial (NCT04315948; EudraCT 2020-000936-23), randomized to either standard of care (SoC) or SoC + remdesivir. We used a mathematical model to reconstruct viral kinetic profiles and estimate the antiviral efficacy of remdesivir in blocking viral replication. Additional analyses were conducted stratified on time of treatment initiation (≤7 or >7 days since symptom onset) or viral load at randomization (< or ≥3.5 log10 copies/104 cells).Results: In our model, remdesivir reduced viral production by infected cells by 2-fold on average (95% CI: 1.5-3.2-fold). Model-based simulations predict that remdesivir reduced time to viral clearance by 0.7 days compared with SoC, with large inter-individual variabilities (IQR: 0.0-1.3 days). Remdesivir had a larger impact in patients with high viral load at randomization, reducing viral production by 5-fold on average (95% CI: 2.8-25-fold) and the median time to viral clearance by 2.4 days (IQR: 0.9-4.5 days).Conclusions: Remdesivir halved viral production, leading to a median reduction of 0.7 days in the time to viral clearance compared with SoC. The efficacy was larger in patients with high viral load at randomization. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index